Simcere was Awarded “2019 Best Industrial Enterprise in China's Pharmaceutical R&D Product Line”

微信图片_20190827095654.jpg

On August 25, the 2019 (36th) National Medicinal Industry Information Annual Conference, hosted by China Pharmaceutical Industry Information Center, was held grandly in Lianyungang. The conference released the list of 2019 Best Industrial Enterprise in China's Pharmaceutical R&D Product Line. Simcere was once again awarded the “Best Industrial Enterprise in China's Pharmaceutical R&D Product Line”, which is the seventh consecutive year that Simcere Pharmaceutical has been awarded this title. 

lalallalala.png


The “Best Industrial Enterprises in China's Pharmaceutical R&D Product Line” are selected by experts of China National Pharmaceutical Industry Information Center in a fair, objective and authoritative manner. This event aims to track the R&D progress of pharmaceutical industry domestically and overseas, and unearth the strongest voice in domestic pharmaceutical research and development field, investigate deeply the trends of industry reform, select promising players with the highest investing value in China’s pharmaceutical industry, and promote the healthy and rapid development of the entire industry by drawing upon the successful experience of the top researchers. The results of the selection have received wide attention and recognition across the industry. 

640.webp.jpg


Simcere is committed to becoming a leader in innovative medicine research and development in China. In recent years, it has continued to increase R&D investment, actively expanded international cooperation and established R&D organizations in its biotechnology centers. In early 2018, Simcere’s Shanghai Innovation Center was established in Shanghai International Medical Zone in Zhangjiang, which has attracted hundreds of returned scientists and young, energetic R&D talents to join the Center. In 2019, it officially started to build the Boston Innovation Center and recruit innovative partners and collaborative R&D projects on a global scale. In terms of the research pipeline, two of its blockbuster innovative medicine have passed clinical trial and are waiting for approval.



References
Related News